Back to Awarded Treatment Trials


Awarded Trial: 02T-251

Grant ID

02T-251

Illness

Schizophrenia

Primary Drug/Intervention

Pimozide

Primary Dosage

2mg-8mg

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Gunduz-Bruce

Sample Size

60

Duration of Study Period for Each Subject

12 weeks

Outcome Measurements

BPRS, SANS, AIMS, Simpson-Angus, Modified Barnes Akathisia Scale, cognitive battery

Results

Pimozide or placebo were used as augmentation for 32 schizophrenia patients partially responsive to clozapine for 12 weeks. 28 completed the trial. There were no significiant differences on BPRS, SANS, or the psychosis or depression subscales but it did have a significant effect on verbal working memory (digit span).

Publication

Being submitted.

Link

N/A

PI Name

Handan Gunduz-Bruce

Degree

MD

Center

VA CT Healthcare System

Institution

Yale University School of Medicine

Address

950 Campbell Ave

City or Town

West Haven

State or Province

CT

Zip or Postal Code

6516

Country

USA

Email Address

handan.gunduz-bruce@yale.edu